Common Side Effects and Monitoring Needs
Lurbinectedin (brand name Zepzelca) causes frequent side effects like low blood cell counts (neutropenia, anemia, thrombocytopenia), fatigue, nausea, decreased appetite, musculoskeletal pain, diarrhea, vomiting, dyspnea, and edema. Patients need regular complete blood count monitoring during treatment, with dose delays or reductions if counts drop significantly.[1]
Myelosuppression Precautions
This drug suppresses bone marrow, increasing infection, bleeding, and fatigue risks. Avoid use in patients with active infection or severe bone marrow issues. Prophylactic G-CSF may be required for neutropenia; hold treatment if absolute neutrophil count falls below 500 cells/μL or platelets below 50,000 cells/μL.[1]
Liver and Kidney Function Checks
Monitor liver enzymes (ALT, AST, bilirubin) before each cycle, as hepatotoxicity occurs in up to 10% of patients. Reduce dose or discontinue if severe. Use caution in moderate renal impairment (CrCl 30-89 mL/min); avoid in end-stage renal disease.[1]
Drug Interactions to Avoid
Strong CYP3A inhibitors (e.g., ketoconazole) increase lurbinectedin exposure—avoid or separate by 5 half-lives. Strong CYP3A inducers (e.g., rifampin) decrease efficacy—avoid. No major interactions with moderate inhibitors/inducers, but monitor closely.[1]
Pregnancy, Fertility, and Contraception Warnings
Embryofetal toxicity risk means avoid during pregnancy (Category D). Use effective contraception during treatment and for 6 months after in females; 4 months in males. Lurbinectedin may impair male fertility—advise sperm banking.[1]
Administration and Infusion Precautions
Administer IV over 60 minutes every 21 days. Premedicate with antiemetics (dexamethasone, serotonin antagonist, NK1 antagonist) to prevent nausea/vomiting. Watch for hypersensitivity during infusion; have emergency equipment ready.[1]
Who Should Avoid It?
Contraindicated in severe hypersensitivity to lurbinectedin. Use cautiously in elderly patients (higher toxicity risk) or those with performance status >1. Not studied in pediatric patients or severe hepatic impairment.[1]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, https://www.zepzelca.com/